FibrosarcomaSymptoms, Doctors, Treatments, Advances & More
Learn About Fibrosarcoma
- Fibrosarcoma
Cleveland Clinic Main Campus
Gary Schwartz is a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 47 years. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Hepato-Pancreato-Biliary Surgery, and Liver Embolization. Dr. Schwartz is board certified in American Board Of Internal Medicine, 1986.
UT MD Anderson Cancer Center
Christina Roland is a Surgical Oncologist practicing medicine in Cary, North Carolina. Dr. Roland is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.
Rockefeller Outpatient Pavilion
Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.
Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...
Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center